For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

FDA approves suzetrigine, a non-opioid painkiller that blocks sodium channels, offering potent relief without addiction risks.

In 2004, a research group at Peking University First Hospital discovered a mutation in the gene coding for a sodium-channel ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, ...

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for adults experiencing moderate to severe acute pain. Journavx received FDA ...

Journavx (suzetrigine) is said to reduce pin by "targeting a pain-signaling pathway involving sodium channels in the ...

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.